Crossmark

Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study

Crossref DOI link: https://doi.org/10.1186/s12885-021-08275-9

Published Online: 2021-05-13

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chang, Chen

Li, Xiaofen

Cao, Dan
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81773097)
License Information

Text and Data Mining valid from 2021-05-13

Version of Record valid from 2021-05-13
More Information

Article History

Received: 28 March 2021

Accepted: 29 April 2021

First Online: 13 May 2021

Declarations

:

: The study is approved by Chinese Ethics Committee of Registering Clinical Trials (ChiECRCT20190240). The research process must be carried out in strict accordance with the requirements of the SFDA Quality Control Practice for Drug Clinical Trials and the Helsinki Declaration. The patient or his legal representative should read and understand and sign the informed consent form for chemotherapy and keep it in the medical record.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below